- Disease: Acute COVID-19
- Study type: Observational Cohort Study, Treatment
- Study type descriptors: Retrospective, Multicentre
- Objective: To investigate the effect of compassionate use of plitidepsin as an antiviral therapy in immunocompromised COVID-19 patients with underlying haematological malignancies or solid tumors, particularly those who have undergone anti-CD20 therapies
- Number of participants enrolled: 54
- Study enrolling from to
- Study includes follow-up for 1 month
Sites (6)
- Hospital Clínic de Barcelona (Barcelona, Spain)
- MD Anderson Cancer Center Madrid (Madrid, Spain)
- Hospital Universitario Quirónsalud Madrid (Madrid, Spain)
- Hospital Universitario HM Sanchinarro (Madrid, Spain)
- Hospital Universitario de Burgos (Burgos, Spain)
- Hospital HLA Universitario Moncloa (Madrid, Spain)
Study Data
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Plitidepsin
External Links
Other information
Funders/Sponsors:
- PharmaMar S.A., Colmenar Viejo, Spain
- Hospital Universitario QuironSalud Madrid
The information was provided with the aid of the study investigators
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to